All In Biotech

Drug Trial Radar · NCT00555061

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months

Last checked: Nov 20, 2026Latest source record: Dec 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Sep 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 7, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 months, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Conditions

  • Skin Infections, Bacterial

Interventions

  • Retapamulin Ointment, 1%Drug

    1% Ointment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Measurable Plasma Concentrations, by Age GroupTime frame: Days 3 to 4; 4 to 8 hours post-dose of the first dose of the day

Locations

25 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Bentonville, Arkansas

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    Woburn, Massachusetts

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    Santiago, Región Metro de Santiago, Chile

  • GSK Investigational Site

    San José, Costa Rica

  • GSK Investigational Site

    Nördlingen, Bavaria, Germany

  • GSK Investigational Site

    Bochum, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Erkrath, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Goch, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Kleve-Materborn, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    México, Mexico

  • GSK Investigational Site

    Alphen aan den Rijn, Netherlands

  • GSK Investigational Site

    Losser, Netherlands

  • GSK Investigational Site

    Roelofarendsveen, Netherlands

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Soerendonk, Netherlands

  • GSK Investigational Site

    Woerden, Netherlands

  • GSK Investigational Site

    Benoni, South Africa

  • GSK Investigational Site

    Newtown, South Africa

  • GSK Investigational Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.